Gensight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa

Impact · against what's priced in

The publication of GS030 Phase 1/2 trial results in the NEJM provides a positive catalyst for GenSight Biologics. This academic validation typically enhances institutional credibility and streamlines the path toward Phase 3 partnerships and regulatory review.

SIGHT+0.40: No priced-in read yet

Gensight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa

What matters in this story

How each ticker is affected

Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility

Gensight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa

What matters in this story

How each ticker is affected

Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility

Track these names every morning.

Futura Medical revises sale timetable as finance director steps down

UCB SA (UCBJY) Discusses EADV Data Highlights and Long-Term Impact of BIMZELX in Dermatology Transcript

U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes

Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older

Gensight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa

What matters in this story

How each ticker is affected

Next reads from the same story arc

Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility

Gensight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa

What matters in this story

How each ticker is affected

Next reads from the same story arc

Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility

Track these names every morning.

Futura Medical revises sale timetable as finance director steps down

UCB SA (UCBJY) Discusses EADV Data Highlights and Long-Term Impact of BIMZELX in Dermatology Transcript

U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes

Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older